Abstract
Many patients suffering from head and neck squamous cell carcinoma (HNSCC) do not benefit from cetuximab added to radiotherapy. Some of the mechansisms leading to resistance to the combined treatment are already understood. However, they do not fully explain the resistance to multimodal therapy. In this review, potential mechanisms of resistance to therapy will be addressed, starting from the outside of the cells looking at the potential role the ECM may play, then continuing with EGF receptor alterations, which may contribute to resistance to therapy with antibodies. The role of FcγRIIIa receptor polymorphism in antibody-dependent cell-mediated cytotoxicity (ADCC), which may be a mechanism of anticancer activity of cetuximab will be discussed, as well as the resistance to radiotherapy and receptor blocking therapy mediated by the insulin-like growth factor receptor I (IGF-1R). Inside the cell, proteins expressed in radioresistant cells will be highlighted before turning the attention to the impact epithelial mesenchymal transition (EMT) may have on increased resistance to different treatment modalities. The last section of this review aims to outline potential treatment approaches, which, in the future, may help improve treatment response.
Keywords: Resistance to radiotherapy, targeted therapy, combined therapy, squamous cell carcinoma of the head and neck (HNSCC), metalloproteinases, Polymorphisms, cytoskeleton, heterodimers, cetuximab
Current Signal Transduction Therapy
Title:Resistance to Radiotherapy and Targeted Molecular Therapies in Squamous Cell Carcinomas of the Head and Neck, Preclinical Data and New Approaches
Volume: 7 Issue: 3
Author(s): Eva-Maria Schottdorf
Affiliation:
Keywords: Resistance to radiotherapy, targeted therapy, combined therapy, squamous cell carcinoma of the head and neck (HNSCC), metalloproteinases, Polymorphisms, cytoskeleton, heterodimers, cetuximab
Abstract: Many patients suffering from head and neck squamous cell carcinoma (HNSCC) do not benefit from cetuximab added to radiotherapy. Some of the mechansisms leading to resistance to the combined treatment are already understood. However, they do not fully explain the resistance to multimodal therapy. In this review, potential mechanisms of resistance to therapy will be addressed, starting from the outside of the cells looking at the potential role the ECM may play, then continuing with EGF receptor alterations, which may contribute to resistance to therapy with antibodies. The role of FcγRIIIa receptor polymorphism in antibody-dependent cell-mediated cytotoxicity (ADCC), which may be a mechanism of anticancer activity of cetuximab will be discussed, as well as the resistance to radiotherapy and receptor blocking therapy mediated by the insulin-like growth factor receptor I (IGF-1R). Inside the cell, proteins expressed in radioresistant cells will be highlighted before turning the attention to the impact epithelial mesenchymal transition (EMT) may have on increased resistance to different treatment modalities. The last section of this review aims to outline potential treatment approaches, which, in the future, may help improve treatment response.
Export Options
About this article
Cite this article as:
Schottdorf Eva-Maria, Resistance to Radiotherapy and Targeted Molecular Therapies in Squamous Cell Carcinomas of the Head and Neck, Preclinical Data and New Approaches, Current Signal Transduction Therapy 2012; 7 (3) . https://dx.doi.org/10.2174/157436212802481574
DOI https://dx.doi.org/10.2174/157436212802481574 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Regulation and Function of Antimicrobial Peptides in Immunity and Diseases of the Lung
Protein & Peptide Letters Apigenin Inhibits Proliferation, Migration, and Invasion of Human Tongue Carcinoma Tca8113 Cells Through Regulating the MAPK Signaling Pathways
Current Molecular Medicine Design Strategies, Structures and Molecular Interactions of Small Molecule Src Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Anti-Inflammatory Effects of Triterpenoids; Naturally Occurring and Synthetic Agents
Mini-Reviews in Organic Chemistry From HPV Infection to Oncogenesis: A Brief Review of the Complex Immunobiological Events
Current Cancer Therapy Reviews Carvacrol Exhibits Chemopreventive Potential against Cervical Cancer Cells via Caspase-Dependent Apoptosis and Abrogation of Cell Cycle Progression
Anti-Cancer Agents in Medicinal Chemistry Inhibition of Aurora A Kinase by Alisertib Induces Autophagy and Cell Cycle Arrest and Increases Chemosensitivity in Human Hepatocellular Carcinoma HepG2 Cells
Current Cancer Drug Targets Non-steroidal Anti-Inflammatory Drugs and Melanoma
Current Pharmaceutical Design MicroRNA Levels in Cervical Cancer Samples and Relationship with Lesion Grade and HPV Infection
MicroRNA CXCL12-CXCR4 Axis in Angiogenesis, Metastasis and Stem Cell Mobilization
Current Pharmaceutical Design Management of Gene Variants of Unknown Significance: Analysis Method and Risk Assessment of the VHL Mutation p.P81S (c.241C>T)
Current Genomics Targeting MET Receptor in Rhabdomyosarcoma: Rationale and Progress
Current Drug Targets Pentoxifylline Use in Dermatology
Inflammation & Allergy - Drug Targets (Discontinued) Adrenergic Receptors as Targets for Cancer Treatment - A Perspective for Future Studies
Current Cancer Therapy Reviews A Critical Review of Second-Generation Anti-EGFR Monoclonal Antibodies in Metastatic Colorectal Cancer
Current Drug Targets A New Approach for Cancer Immunotherapy Based on the Cancer Stem Cell Antigens Properties
Current Molecular Medicine Screening Novel SAHA Derivatives as Anti-lung Carcinoma Agents: Synthesis, Biological Evaluation, Docking Studies and Further Mechanism Research between Apoptosis and Autophagyetween Apoptosis and Autophagy
Anti-Cancer Agents in Medicinal Chemistry Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck
Anti-Cancer Agents in Medicinal Chemistry The Adrenergic System in Gastrointestinal Cancers
Current Cancer Therapy Reviews EGFR-Targeted Therapy in Malignant Glioma: Novel Aspects and Mechanisms of Drug Resistance
Current Molecular Pharmacology